We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Deciphera Pharmaceuticals (DCPH) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Deciphera Pharmaceuticals, Inc. (DCPH - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Deciphera Pharmaceuticals, Inc. is a member of our Medical group, which includes 1190 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Deciphera Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for DCPH's full-year earnings has moved 9.8% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, DCPH has returned 38.4% so far this year. Meanwhile, the Medical sector has returned an average of -12.3% on a year-to-date basis. This shows that Deciphera Pharmaceuticals, Inc. is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Evolus, Inc. (EOLS - Free Report) . The stock is up 110.8% year-to-date.
The consensus estimate for Evolus, Inc.'s current year EPS has increased 15.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Deciphera Pharmaceuticals, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 558 individual companies and currently sits at #82 in the Zacks Industry Rank. On average, stocks in this group have lost 19.5% this year, meaning that DCPH is performing better in terms of year-to-date returns.
On the other hand, Evolus, Inc. belongs to the Medical - Products industry. This 100-stock industry is currently ranked #87. The industry has moved -24% year to date.
Investors with an interest in Medical stocks should continue to track Deciphera Pharmaceuticals, Inc. and Evolus, Inc. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Deciphera Pharmaceuticals (DCPH) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Deciphera Pharmaceuticals, Inc. (DCPH - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Deciphera Pharmaceuticals, Inc. is a member of our Medical group, which includes 1190 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Deciphera Pharmaceuticals, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for DCPH's full-year earnings has moved 9.8% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the most recent data, DCPH has returned 38.4% so far this year. Meanwhile, the Medical sector has returned an average of -12.3% on a year-to-date basis. This shows that Deciphera Pharmaceuticals, Inc. is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Evolus, Inc. (EOLS - Free Report) . The stock is up 110.8% year-to-date.
The consensus estimate for Evolus, Inc.'s current year EPS has increased 15.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Deciphera Pharmaceuticals, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 558 individual companies and currently sits at #82 in the Zacks Industry Rank. On average, stocks in this group have lost 19.5% this year, meaning that DCPH is performing better in terms of year-to-date returns.
On the other hand, Evolus, Inc. belongs to the Medical - Products industry. This 100-stock industry is currently ranked #87. The industry has moved -24% year to date.
Investors with an interest in Medical stocks should continue to track Deciphera Pharmaceuticals, Inc. and Evolus, Inc. These stocks will be looking to continue their solid performance.